Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary

• Lucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of six analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -24 cents to -10 cents per share.

• Revenue rose 15.1% to $1.20 million from a year ago; analysts expected $1.42 million.

• Lucid Diagnostics Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of $11.54 million.

• Lucid Diagnostics Inc shares had risen by 85.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00

This summary was machine generated from LSEG data March 24 at 02:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)